Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285981736> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- W4285981736 endingPage "B14" @default.
- W4285981736 startingPage "B14" @default.
- W4285981736 abstract "Although immune checkpoint inhibitor(ICI) therapy represents a breakthrough in advanced cancer treatment, further research into immune related adverse events (irAEs) and their management is warranted. Cutaneous irAEs (cirAEs) represent an early irAE for which systemic corticosteroids(SCS) are recommended, depending on their severity and morphology. We sought to investigate the impact of SCS exposure and dose on survival outcomes when administered during cirAE episodes. In this retrospective, single-institution study, we screened patients receiving ICI therapy between 1/1/16-6/29/21 and confirmed cirAE status using previously defined criteria. Patients identified as having cirAE were chart reviewed for additional demographic and clinical information including SCS exposure. SCS exposure was categorized by indication (cirAE, irAE, or other medical condition) and dosage (“low,” ≤7.5 mg prednisone equivalents (eqs)/day for ≥2 months; “moderate,” >7.5 mg prednisone eqs/day for ≥2 months; “high,” ≥1mg/kg prednisone eqs/day for ≥1 week). Cox proportional hazard models were used to assess the relationship between SCS and survival outcomes, such as progression free survival (PFS) and overall survival (OS) while controlling for potential confounders. Of 628 patients who developed cirAEs, one-third (n=209, 33.3%) of patients were exposed to SCS during their cirAE episode for any cause. Out of those receiving SCS, 66.0% (n=138) received a “low” dose, 12.0% (n=25) received a “moderate” dose, and 22.0% (n=46), received a “high” dose. SCS use was associated with decreased OS (HR 1.41, p<0.05). When comparing high-dose versus low- and moderate-doses, no difference was found in PFS (HR: 0.79, p-value=.22) or OS (HR: 0.96, p-value=0.20). Results suggest SCS exposure during cirAE may worsen OS. Oncologists and dermatologists should avoid SCS exposure if possible." @default.
- W4285981736 created "2022-07-20" @default.
- W4285981736 creator A5004535558 @default.
- W4285981736 creator A5013275285 @default.
- W4285981736 creator A5017615032 @default.
- W4285981736 creator A5026080631 @default.
- W4285981736 creator A5036816475 @default.
- W4285981736 creator A5079832798 @default.
- W4285981736 creator A5086369235 @default.
- W4285981736 date "2022-08-01" @default.
- W4285981736 modified "2023-10-01" @default.
- W4285981736 title "LB933 Systemic corticosteroid exposure during cutaneous immune related adverse events worsens overall survival" @default.
- W4285981736 doi "https://doi.org/10.1016/j.jid.2022.05.951" @default.
- W4285981736 hasPublicationYear "2022" @default.
- W4285981736 type Work @default.
- W4285981736 citedByCount "0" @default.
- W4285981736 crossrefType "journal-article" @default.
- W4285981736 hasAuthorship W4285981736A5004535558 @default.
- W4285981736 hasAuthorship W4285981736A5013275285 @default.
- W4285981736 hasAuthorship W4285981736A5017615032 @default.
- W4285981736 hasAuthorship W4285981736A5026080631 @default.
- W4285981736 hasAuthorship W4285981736A5036816475 @default.
- W4285981736 hasAuthorship W4285981736A5079832798 @default.
- W4285981736 hasAuthorship W4285981736A5086369235 @default.
- W4285981736 hasBestOaLocation W42859817361 @default.
- W4285981736 hasConcept C126322002 @default.
- W4285981736 hasConcept C167135981 @default.
- W4285981736 hasConcept C197934379 @default.
- W4285981736 hasConcept C207103383 @default.
- W4285981736 hasConcept C2776804153 @default.
- W4285981736 hasConcept C2778720950 @default.
- W4285981736 hasConcept C44249647 @default.
- W4285981736 hasConcept C50382708 @default.
- W4285981736 hasConcept C71924100 @default.
- W4285981736 hasConcept C77350462 @default.
- W4285981736 hasConcept C90924648 @default.
- W4285981736 hasConceptScore W4285981736C126322002 @default.
- W4285981736 hasConceptScore W4285981736C167135981 @default.
- W4285981736 hasConceptScore W4285981736C197934379 @default.
- W4285981736 hasConceptScore W4285981736C207103383 @default.
- W4285981736 hasConceptScore W4285981736C2776804153 @default.
- W4285981736 hasConceptScore W4285981736C2778720950 @default.
- W4285981736 hasConceptScore W4285981736C44249647 @default.
- W4285981736 hasConceptScore W4285981736C50382708 @default.
- W4285981736 hasConceptScore W4285981736C71924100 @default.
- W4285981736 hasConceptScore W4285981736C77350462 @default.
- W4285981736 hasConceptScore W4285981736C90924648 @default.
- W4285981736 hasIssue "8" @default.
- W4285981736 hasLocation W42859817361 @default.
- W4285981736 hasOpenAccess W4285981736 @default.
- W4285981736 hasPrimaryLocation W42859817361 @default.
- W4285981736 hasRelatedWork W182517381 @default.
- W4285981736 hasRelatedWork W2013481362 @default.
- W4285981736 hasRelatedWork W2078812006 @default.
- W4285981736 hasRelatedWork W2112683812 @default.
- W4285981736 hasRelatedWork W2136543019 @default.
- W4285981736 hasRelatedWork W2511583075 @default.
- W4285981736 hasRelatedWork W2600917178 @default.
- W4285981736 hasRelatedWork W2987929566 @default.
- W4285981736 hasRelatedWork W2997776675 @default.
- W4285981736 hasRelatedWork W3165911358 @default.
- W4285981736 hasVolume "142" @default.
- W4285981736 isParatext "false" @default.
- W4285981736 isRetracted "false" @default.
- W4285981736 workType "article" @default.